BIND Therapeutics, a biopharma company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has entered into a global collaboration agreement with Pfizer to develop and commercialize Accurins utilizing select small molecule targeted therapies. The collaboration will use BIND’s Medicinal Nanoengineering platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs.
 
Pfizer will have the exclusive option to pursue development and commercialization of selected Accurins. Both companies will work together on preclinical research and Pfizer will have responsibility for further development and commercialization. BIND could receive up-front and development milestone payments totaling approximately $50 million and $160 million in regulatory and sales milestones for each Accurin commercialized, as well as royalties on sales.
 
“Pfizer is an outstanding partner and this agreement demonstrates the potential of our platform to create targeted Accurins with optimized therapeutic properties,” said Scott Minick, resident and chief executive officer of BIND. “This is our second collaboration focused on developing novel Accurins based on BIND’s platform for targeted and programmable therapeutics and further validates the importance of targeted nanomedicines as a strategic technology for the pharma industry.”